Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Dynavax Technologies Corporation (DVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: DVAX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $23.25
1 Year Target Price $23.25
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.33% | Avg. Invested days 39 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.27B USD | Price to earnings Ratio - | 1Y Target Price 23.25 |
Price to earnings Ratio - | 1Y Target Price 23.25 | ||
Volume (30-day avg) 4 | Beta 1.09 | 52 Weeks Range 9.22 - 14.63 | Updated Date 08/15/2025 |
52 Weeks Range 9.22 - 14.63 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.096 | Actual 0.1916 |
Profitability
Profit Margin -16.67% | Operating Margin (TTM) 17.45% |
Management Effectiveness
Return on Assets (TTM) 0.52% | Return on Equity (TTM) -9.28% |
Valuation
Trailing PE - | Forward PE 29.24 | Enterprise Value 917149658 | Price to Sales(TTM) 4 |
Enterprise Value 917149658 | Price to Sales(TTM) 4 | ||
Enterprise Value to Revenue 2.9 | Enterprise Value to EBITDA 30.92 | Shares Outstanding 117267000 | Shares Floating 98911603 |
Shares Outstanding 117267000 | Shares Floating 98911603 | ||
Percent Insiders 0.6 | Percent Institutions 100.2 |
Upturn AI SWOT
Dynavax Technologies Corporation
Company Overview
History and Background
Dynavax Technologies Corporation was founded in 1996. Initially focused on immunostimulatory sequences (ISS), it evolved into a commercial-stage biopharmaceutical company, achieving a significant milestone with the FDA approval of HEPLISAV-B, a hepatitis B vaccine.
Core Business Areas
- Commercial Products: Focuses on the commercialization and sale of HEPLISAV-B, a hepatitis B vaccine for adults.
- Research and Development: Engaged in research and development activities, including potential new vaccines and immuno-oncology programs.
Leadership and Structure
Ryan Spencer serves as the Chief Executive Officer. The organizational structure includes departments for research and development, commercial operations, and finance, among others, reporting to executive leadership.
Top Products and Market Share
Key Offerings
- HEPLISAV-B: HEPLISAV-B is a hepatitis B vaccine for adults. Revenue is primarily derived from sales of HEPLISAV-B. Competitors include Engerix-B (GSK) and Recombivax HB (Merck). HEPLISAV-B held approximately 25% of the US market share as of 2023.
Market Dynamics
Industry Overview
The market consists of vaccines, particularly hepatitis B vaccines, and related preventative healthcare products. Growth is driven by increasing awareness of infectious diseases, government immunization programs, and aging populations.
Positioning
Dynavax is a player in the vaccine market, with a competitive advantage in HEPLISAV-B's efficacy and dosing schedule. Its positioning is strengthened by partnerships and commercialization efforts.
Total Addressable Market (TAM)
The global hepatitis B vaccine market is projected to reach $4.5 billion by 2027. Dynavax is positioned to capture a significant portion of this TAM through HEPLISAV-B and future product development.
Upturn SWOT Analysis
Strengths
- HEPLISAV-B's efficacy and convenience.
- Established commercial infrastructure.
- Experienced management team.
- Proprietary adjuvant technology.
Weaknesses
- Reliance on a single commercial product (HEPLISAV-B).
- Competition from established players.
- Need for further pipeline development.
- Market penetration barriers.
Opportunities
- Expanding HEPLISAV-B market share.
- Developing new vaccine candidates.
- Entering new geographic markets.
- Leveraging adjuvant technology in other applications.
Threats
- Competition from other hepatitis B vaccines.
- Adverse events or safety concerns.
- Changes in government regulations or reimbursement policies.
- Generic competition in the long term.
Competitors and Market Share
Key Competitors
- GSK (GSK)
- MRK (MRK)
Competitive Landscape
Dynavax's competitive advantage lies in HEPLISAV-B's efficacy. Disadvantages include reliance on a single product and smaller scale compared to GSK and Merck.
Growth Trajectory and Initiatives
Historical Growth: Dynavax Technologies Corporation has experienced revenue growth driven by HEPLISAV-B sales.
Future Projections: Analysts project continued revenue growth driven by HEPLISAV-B, with potential upside from new product development.
Recent Initiatives: The company has focused on expanding its commercial reach for HEPLISAV-B and advancing its research and development pipeline.
Summary
Dynavax has a strong product in HEPLISAV-B that is contributing to increased revenues and profitability. Reliance on one product and the presence of larger competitors are risks. Expansion of the product line and partnerships are key for sustained growth. Market penetration must continue to increase to capture a larger share of the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dynavax Technologies Corporation
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2004-02-19 | CEO & Director Mr. Ryan Spencer | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 405 | Website https://www.dynavax.com |
Full time employees 405 | Website https://www.dynavax.com | ||
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.